WuXi Pharmatech and OMT expand antibodies agreement PMLiVE Chinese contract research organisation (CRO) WuXi Pharmatech and US therapeutic antibodies developer Open Monoclonal Technology (OMT) have agreed to expand WuXi's use of OMT's antibodies technology across Asia. The agreement enables WuXi to ... |
